Trastuzumab is a human epidermal growth factor receptor (HER)-2/neu inhibitor approved by the US Food and Drug Administration for the treatment of HER-2–positive breast cancer.

Neuroendocrine tumors (NETs) represent a spectrum of rare neoplasms derived from cells of the nervous and endocrine systems.

In an effort to improve response rates to chemotherapy, agents often are combined to give a so-called twoprong attack against tumor cells.

Bevacizumab-based Therapy Improves Outcomes in Elderly Patients with NSCLC
Background: Efficacy and safety data of bevacizu mab plus cisplatin/gemcitabine for elderly patients with non–small-cell lung cancer (NSCLC) could be extracted through subgroup analysis of patients in the AVAiL trial.

Therapy options for castration- resistant metastatic prostate cancer have expanded in 2010 with two new distinctly different modalities. Sipuleucel-T is a cellular immunotherapy consisting of activated antigen-presenting cells combined ex vivo with prostatic acid phosphatase and granulocyte- macrophage colony-stimulating factor and immersed in autologous peripheral blood mononuclear cells.

North America is facing a shortage of certain drugs, and you do not have to be a pharmacist buyer tasked with procurement to realize our drug supply is under pressure.

Virtually all patients that succumb to prostate cancer die of metastatic castration-resistant disease. Doce taxel, the standard of care for these patients, provides a modest prolongation of survival, but there is an urgent need for novel treatment strategies. Recently, the biological and molecular mechanisms driving prostate cancer growth and progression have become better understood, and this has resulted in widespread clinical testing of numerous new targeted therapies. At least some of these may extend and ideally even save the lives of the 218,000 men who develop this disease annually, some 32,000 of whom will die of prostate cancer under current therapies.¹